Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production

Lupus

Volumn 11, Issue 12, 2002, Pages 850-855

  Mageed, R A ^a   Isenberg, D A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antibodies; Cytokines; Lupus

Indexed keywords

AUTOANTIBODY; DNA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE COURSE; HUMAN; IMMUNOMODULATION; INFLAMMATION; LYMPHOID ORGAN; NONHUMAN; ORGANOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL;

ANIMALS; ANTIBODIES, ANTINUCLEAR; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036945201     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu306rr     Document Type: Conference Paper

References (45)

1. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280: 243-248.
2. Moore P, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.
3. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
4. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999; 57(Suppl): 16-21.
5. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998; 10: 669-676.
6. Riminton DS, Sedgwick JD. Novel concepts of tumor necrosis factor action in autoimmune pathology. Curr Dir Autoimmun 2000; 2: 50-82.
7. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci USA 1990; 87: 968-972.
8. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, McDevitt HO. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994; 180: 995-1004.
9. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996; 184: 1963-1974.
10. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997; 185: 1573-1584.
11. Maini RN, Elliott MJ, Brennan FM, et al. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995; 144: 195-223.
12. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547-349.
13. Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 1997; 159: 2867-2876.
14. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002; 14: 204-211.
15. Bauditz J, Lochs H, Schreiber S. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New Engl J Med 1998; 338: 334.
16. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. New Engl J Med 2002; 346: 1349-1356.
17. Jacob CO and McDevitt HO. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 1988; 331: 356-358.
18. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-2390.
19. Jacob CO, Hwang F. Definition of microsatellite size variants for Tnfa and Hsp70 in autoimmune and nonautoimmune mouse strains. Immunogenetics 1992; 36: 182-188.
20. Richter G, Qin ZH, Diamantstein T, Blankenstein T. Analysis of restriction fragment length polymorphism in lymphokine genes of normal and autoimmune mice. J Exp Med 1989; 170: 1439-1443.
21. Jacob CO, Lee SK, Strassman G. Mutational analysis of TNFα gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 1996; 156: 3043-3050.
22. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-310.
23. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989; 52: 421-434.
24. Edwards CK III, Zhou T, Zhang J, Baker TJ, De M, Long RE, Borcherding DR, Bowlin TL, Bluethmann H, Mountz JD. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J Immunol 1996; 157: 1758-1772.
25. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-alpha in MRL-Ipr mice with differing regulatory mechanisms. Kidney Int 1995; 47: 122-130.
26. Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis Rheum 1982; 25: 55-60.
27. Lee SH, Park SH, Min JK et al. Decreased tumour necrosis factor-beta production in TNFB*2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 1997; 6: 603-609.
28. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumomecrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87: 1233-1237.
29. Wilson AG, Gordon C, di Giovine FS, de Vries N, van de Putte LB, Emery P, Duff GW. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 1994; 24: 191-195.
30. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
31. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995-1996; 46: 32-41.
32. Stuber F, Udalova IA, Book M et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter, J Inflamm 1995-1996; 46: 42-50.
33. Pociot F, Wilson AG, Nerup J, Duff GW. No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 3050-3053.
34. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-1074.
35. Kaliyaperumal A, Mohan C, Wu W and Datta SK. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 1996; 183: 2459-2469.
36. Ebling FM, Tsao BP, Singh RR, Sercarz E, Hahn BH. A peptide derived from an autoantibody can stimulate T cells in the (NZBxNZW) F1 mouse model of systemic lupus erythematosus. Arthritis Rheum 1993; 36: 355-364.
37. Reininger L, Winkler TH, Kalberer CP, Jourdan M, Melchers F, Rolink AG, Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZBxNZW) F1 mice. J Exp Med 1996; 184: 853-861.
38. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
39. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol 1990; 144: 1753-1758.
40. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001; 167: 6821-6826.
41. Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000; 30(7): 2038-2047.
42. Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5: 694-697.
43. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
44. Ray SK, Putterman C, Diamond B, Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci USA 1996; 93: 2019-2024.
45. Menges M, Rossner S, Voigtlander C et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002; 195: 15-21.